Promising Findings on Kidney Function Preservation in IgA Nephropathy Patients at National Kidney Foundation Spring Clinical Meetings
May 16, 2024
May 16, 2024
LONG BEACH, California, May 16 (TNSres) -- The National Kidney Foundation issued the following news release:
A new study to shed light on the long-term nephroprotective potential of sparsentan compared to maximally titrated irbesartan (MT-IRB) in patients with IgA nephropathy (IgAN) is set to be presented as a late-breaking presentation at the National Kidney Foundation 2024 Spring Clinical Meetings.
"Matching-Adjusted Indirect Comparisons of eGFR Slopes in the PRO . . .
A new study to shed light on the long-term nephroprotective potential of sparsentan compared to maximally titrated irbesartan (MT-IRB) in patients with IgA nephropathy (IgAN) is set to be presented as a late-breaking presentation at the National Kidney Foundation 2024 Spring Clinical Meetings.
"Matching-Adjusted Indirect Comparisons of eGFR Slopes in the PRO . . .